# A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

> **NCT06685757** · PHASE3 · RECRUITING · sponsor: **Biogen** · enrollment: 120 (estimated)

## Conditions studied

- Antibody-mediated Rejection

## Interventions

- **DRUG:** Felzartamab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06685757
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-03
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06685757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06685757, "A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06685757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*